Mood Stabilization in Non-Bipolar Patients

First-Line Options

The American Academy of Child and Adolescent Psychiatry recommends lamotrigine as the preferred mood stabilizer for non-bipolar patients due to its effectiveness in preventing depressive episodes without the metabolic side effects associated with other mood stabilizers 1
Valproate can be considered as an alternative first-line option, particularly for patients with impulsivity, aggression, or emotional lability 2

For patients with Obsessive-Compulsive Disorder (OCD) and mood instability, the International College of Obsessive-Compulsive Spectrum Disorders suggests that SSRIs remain the first-line pharmacological treatment 3
The addition of a mood stabilizer to an SSRI may be beneficial for OCD patients with comorbid mood instability after achieving adequate SSRI dosing for at least 8 weeks 3
The presence of specific comorbidities may change the treatment algorithm, with a focus on mood stabilizers plus Cognitive Behavioral Therapy (CBT) in patients with significant mood fluctuations 3

The American Academy of Child and Adolescent Psychiatry notes that lithium has demonstrated anti-suicidal properties and may be considered for non-bipolar patients with suicidal ideation 4
Mood stabilizers should be prioritized over benzodiazepines, as benzodiazepines may disinhibit some individuals and potentially increase aggression and suicide attempts 4

Regular monitoring of medication levels, metabolic parameters, and organ function is essential for patients on mood stabilizers, as recommended by the American College of Clinical Pharmacology 1
For valproate, baseline and regular monitoring (every 3-6 months) should include liver function tests, complete blood cell counts, and pregnancy tests in females 1
For atypical antipsychotics used as mood stabilizers, monitor for weight gain, metabolic syndrome, and extrapyramidal symptoms 1

The treatment duration for non-bipolar patients should be determined based on symptom resolution and risk of recurrence, according to the American College of Clinical Pharmacology 1
A trial of 6-12 months of treatment followed by slow tapering may be considered if symptoms have resolved, as suggested by the National Institute of Mental Health 2

Avoid using antidepressant monotherapy in patients with significant mood instability, as this may worsen mood fluctuations, according to the American Academy of Child and Adolescent Psychiatry 4, 1
Avoid unnecessary polypharmacy while recognizing that some patients will require more than one medication for optimal control, as recommended by the American College of Clinical Pharmacology 1
Do not overlook psychosocial interventions; psychoeducation and cognitive-behavioral therapy should accompany pharmacotherapy to improve outcomes, as suggested by the National Institute of Mental Health 2, 1